Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Center for Genomic Medicine, |
RCV003990185 | SCV004806568 | uncertain significance | Hereditary spastic paraplegia 35 | 2024-03-26 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003990185 | SCV005076567 | likely pathogenic | Hereditary spastic paraplegia 35 | 2024-04-24 | criteria provided, single submitter | clinical testing | Variant summary: FA2H c.688G>A (p.Glu230Lys) results in a conservative amino acid change located in the Fatty acid hydroxylase (IPR006694) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 251198 control chromosomes. c.688G>A has been reported in the literature in at-least four individuals affected with Hereditary Spastic Paraplegia (Cao_2020,5. Wang_2022, Xie_2020). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 23566484, 36109173, 32619247). ClinVar contains an entry for this variant (Variation ID: 3065108). Based on the evidence outlined above, the variant was classified as likely pathogenic. |